Aminalonum

General characteristics. Structure:

Active ingredient: 250 mg of piperidic acid in 1 tablet.

Excipients:  icing sugar, povidone, magnesium stearate, опадрай II (including polyvinyl alcohol, talc, Makrogol 3350 (Polyethyleneglycol), lecithin (soy), titanium dioxide (E 171)), refined sugar, baking wheat flour, magnesium a carbonate the main, titanium dioxide (E 171), beeswax, paraffin, the sunflower oil refined.

Aminalonum has nootropic and anticonvulsant effect.

Pharmacological properties:

Pharmacodynamics. The mechanism of action is connected with ability of Aminalonum to activate piperidic acid (GAMKA-and GAMKV-tipy receptors). Activation GAMKA-retseptorov leads to opening of chloride channels, receipt chloride ions in a cell and to decrease of the activity of neuron. Activation GAMKV-retseptorov is followed by strengthening of metabolic processes in neuron, increase in transport of glucose in a cell, increase in biosynthesis of RNA and protein in neuron.

Aminalonum normalizes dynamics of neuromediator processes in TsNS, increases productivity of thinking, improves processes of consolidation of a memorable trace, favorably influences recovery of motor and speech functions after the postponed ischemic attack.

Aminalonum has moderate anti-hypoxemic and anticonvulsant activity, raises a threshold of convulsive readiness, reduces the frequency of convulsive attacks, significantly without influencing their duration.

Has moderate hypotensive activity, reduces initially increased arterial pressure (AP) and symptoms (dizziness, sleeplessness) connected with it. Slightly urezhat heart rate.

At the persons suffering from a diabetes mellitus reduces glycemia level on an empty stomach. At healthy can have opposite effect due to stimulation of a glycogenolysis.

Pharmacokinetics. After intake it is quickly and almost completely absorbed in the digestive tract (DT). The maximum concentration in a blood plasma is reached in 60 min., after that concentration quickly goes down and by 24 h in a blood plasma is not defined. Badly gets through a blood-brain barrier. In an organism is exposed to bystry and intensive metabolism by transamination in succinateseven-aldehyde and the subsequent oxidation to a-keto-glutaric acid. A part of α-keto-glutaric acid, comes through a blood-brain barrier to the central nervous system (CNS) where is exposed consistently to transamination and decarboxylation in γ-aminobutyric acid acid again.

Indications to use:

- states after the postponed disturbances of cerebral circulation and craniocereberal injuries;

- psychoorganic syndrome;

- atherosclerotic, hypertensive and alcoholic encephalopathy;

- cerebral palsy and effects of a birth trauma at children as a part of complex therapy;

- lag of intellectual development in children;

- kinetoza (sea and aeroembolism).

Route of administration and doses:

Apply inside to food.

To adults and children 7 years are more senior appoint inside 0,5 – 1,25 g 3 times a day.

Daily dose – 1,5 - 3. To children at the age of 6 years – 2,0-3,0 g/days (8-12 tablets) in 3 receptions.

Course of treatment not less than 2-3 weeks (2-4 months are optimum). If necessary courses repeat 1-2 times a year.

At treatment of kinetoz appoint the adult 0,5 g (2 tablets), to children on 0,25 g (1 tablet) 3 times a day during 3-4 days preceding a trip.

Features of use:

Care when using. It is necessary to observe extra care when using Aminalonum at patients with the labile ABP in the first days of treatment, in connection with a possibility of considerable fluctuation of the ABP.

Pregnancy and lactation. At pregnancy and in the period of a lactation safety and efficiency of use of Aminalonum are not established.

Features of influence of drug on ability to manage motor transport or potentially dangerous mechanisms. During use of Aminalonum it is necessary to be careful at control of motor transport or potentially dangerous mechanisms.

Side effects:

- nausea, vomiting, dispepsichesky phenomena;

- fervescence, feeling of heat;

- sleeplessness;

- lability of arterial pressure.

Interaction with other medicines:

At simultaneous use strengthening of the oppressing impact on TsNS of derivatives of benzodiazepine, anticonvulsant and sedative and hypnotic means is possible.

Strengthens effect of hypotensive drugs at use, simultaneous with them.

At combined use with a Vinpocetine, nimodipiny, nitsergoliny at elderly persons development of hypotonia and aggravation of disturbances of cerebral circulation in connection with development of hypoperfusion of a brain against the background of hypotonia is possible.

Contraindications:

- hypersensitivity to Aminalonum;

- children's age up to 6 years.

Overdose:

Aminalonum possesses a hypotoxicity. Symptoms of intoxication arise only at single-step use of extremely high doses of Aminalonum (more than 10-20 g) and are characterized by the following symptoms: nausea, vomiting, stomach ache, fervescence, headache, drowsiness and bradycardia.

Treatment. The specific antidote does not exist. Measures of the help include the drug withdrawal, a gastric lavage with absorbent carbon, purpose of the enveloping means (diosmektit, starch slime) supporting and the symptomatic therapy directed to elimination of the arisen disturbances.

Storage conditions:

In the place protected from light and moisture, at a temperature not over 25 ºС. To store in the place, unavailable to children. A period of validity - 3 years. Not to use after the termination of a period of validity.

Issue conditions:

According to the recipe

Packaging:

On 10 tablets in a blister strip packaging. 5 or 10 blister strip packagings together with a leaf insert place in a pack from a cardboard.